FLT3 Inhibitors for Treating Acute Myeloid Leukemia
- PMID: 27450971
- DOI: 10.1016/j.clml.2016.06.002
FLT3 Inhibitors for Treating Acute Myeloid Leukemia
Abstract
FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed several years ago and include midostaurin, lestaurtinib, sunitinib, and sorafenib. They are relatively nonspecific for FLT3, with other potential targets that include platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and Janus kinase 2. The second-generation inhibitors, including quizartinib, crenolanib, PLX3397, and ASP2215, are more potent and selective than the first-generation inhibitors. The greater potency and selectivity promises greater efficacy in FLT3-mutated acute myelogenous leukemia (AML) (particularly in patients with a greater allele burden) and less toxicity. A number of receptor tyrosine kinase inhibitors are being studied across virtually all disease settings, including frontline, relapsed and refractory, and maintenance, mainly in patients with FLT3-mutated AML. The future of FLT3 inhibitors in the treatment of AML, in combination with chemotherapy or stem cell transplant, appears bright. The present report reviews the current data on FLT3 inhibitors.
Keywords: Acute myelogenous leukemia; Fms-like tyrosine kinase 3; Internal tandem duplication; Sorafenib; Tyrosine kinase inhibitors.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
The Future of Targeting FLT3 Activation in AML.Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2. Curr Hematol Malig Rep. 2017. PMID: 28421420 Review.
-
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Minerva Med. 2020 Oct;111(5):427-442. doi: 10.23736/S0026-4806.20.06989-X. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955823 Review.
-
The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.Hematol Oncol Clin North Am. 2017 Aug;31(4):663-680. doi: 10.1016/j.hoc.2017.03.002. Epub 2017 May 17. Hematol Oncol Clin North Am. 2017. PMID: 28673394 Review.
-
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.Pharmacol Res. 2020 May;155:104725. doi: 10.1016/j.phrs.2020.104725. Epub 2020 Feb 25. Pharmacol Res. 2020. PMID: 32109580 Review.
-
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30. Expert Rev Hematol. 2017. PMID: 29069942 Review.
Cited by
-
Gilteritinib: First Global Approval.Drugs. 2019 Feb;79(3):331-339. doi: 10.1007/s40265-019-1062-3. Drugs. 2019. PMID: 30721452 Review.
-
The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Int J Mol Sci. 2021 Jul 16;22(14):7602. doi: 10.3390/ijms22147602. Int J Mol Sci. 2021. PMID: 34299222 Free PMC article.
-
[Outcome of acute myeloid leukemia with FLT3-ITD mutation treated by allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):634-640. doi: 10.3760/cma.j.issn.0253-2727.2018.08.005. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30180463 Free PMC article. Chinese.
-
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia.Stem Cells Int. 2017;2017:6962379. doi: 10.1155/2017/6962379. Epub 2017 Jan 19. Stem Cells Int. 2017. PMID: 28197208 Free PMC article. Review.
-
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment.Curr Med Chem. 2024;31(29):4657-4686. doi: 10.2174/0109298673277543231205072556. Curr Med Chem. 2024. PMID: 38204232 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
